The menopause is defined as the last menstrual period in a woman's life. It is the inevitable consequence of the natural rate of atresia of ovarian follicles. Because in premenopausal women 95% of circulating oestradiol-Uf is secreted by these follicles, the menopause is associated with a reduction of oestrogen secretion. Measurement of oestrogens by biological techniques showed, many years ago, that blood levels in postmenopausal and castrate women were lower than in premenopausal women. However, even 40 years ago it was realized that oestrogens were not always undetectable in postmenopausal women (Fluhmann 1936).
The menopause is defined as the last menstrual period in a woman's life. It is the inevitable consequence of the natural rate of atresia of ovarian follicles. Because in premenopausal women 95% of circulating oestradiol-Uf is secreted by these follicles, the menopause is associated with a reduction of oestrogen secretion. Measurement of oestrogens by biological techniques showed, many years ago, that blood levels in postmenopausal and castrate women were lower than in premenopausal women. However, even 40 years ago it was realized that oestrogens were not always undetectable in postmenopausal women (Fluhmann 1936) .
The development of biochemical methods of measurement made it possible to investigate extraovarian sources of steroids after the menopause. Direct secretion of oestrogens by the adrenal gland had been inferred by Brown et al. (1959) after noting premenopausal levels of urinary oestrogens in an ovariectomized woman who had been treated with corticotrophin (ACTH). Direct ovarian and adrenal secretion of steroids after the menopause has since been studied by determining hormone concentrations in the blood draining these glands. Although this method of collection of blood samples itself may disturb glandular secretion, the studies reported have suggested that neither the adrenal cortex nor the ovarian stroma makes a significant direct contribution to circulating oestrogens after the menopause (Baird, Uno & Melby 1969 , Judd et al. 1974 .
Extraglandular production of oestrogens through aromatization of androgens was first recognized in humans by West et al. (1956) , who identified oestrone and oestradiol in the urine of 2 adrenalectomized, ovariectomized women after injections of testosterone propionate. The subsequent development of isotopic techniques has allowed this aspect of steroid endocrinology to be studied in greater detail. The peripheral pathways of conversion and interconversion of androgen and oestrogens suggested by the isotopic studies of Baird, Horton et al. (1969) are as follows:
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Recently, Grodin et al. (1973) have concluded that, after the menopause, the amount of oestrone circulating can be entirely accounted for by extraglandular conversion of its prehormone, androstenedione. About two-thirds of the daily production of androstenedione is secreted by the adrenal gland and one-third by the ovarian stroma. The proportion of infused labelled androstenedione that is converted to oestrone increases with body weight ; in vitro studies have confirmed that adipose tissue can aromatize androstenedione (Schindler et al. 1972) . Liver cells also have this enzymatic capacity (Smuk & Schwers 1977) . Oestradiol is thought to be produced by peripheral aromatization of testosterone, and by reduction of oestrone (Baird, Horton et al. 1969) . The sites of these conversions are, however, uncertain.
Determination of the production rates of androgens and oestrogens in postmenopausal women using isotopic methods makes a number of assumptions, such as the existence of steady-state conditions. The secretion of most steroids, however, does not normally occur at a steady rate and the development of radioimmunoassay, by which steroid concentrations in many samples can be determined accurately, has revealed episodic production of many hormones, including steroids. This paper will review some of our results of hormone profile studies in which blood samples have been obtained at frequent intervals from women after the menopause.
Plasma concentration of steroids
A typical profile of the concentrations of androstenedione, testosterone, oestrone and oestradiol in peripheral blood samples obtained every 20 minutes for 24 hours in a postmenopausal woman is shown in Figure 1 parallel fluctuations, with a marked and reproducible diurnal rhythm: the large peak at 14:00 in Figure 1 was presumably stress-related, being associated with an episode of vomiting. A similar pattern of synchronous episodic secretion of cortisol and androstenedione is also seen in premenopausal women (Tunbridge et al. 1973) . It thus appears that in postmenopausal women the rate of secretion ofandrostenedione is regulated, like that of cortisol, predominantly by the rate of secretion of ACTH. Mean androstenedione and testosterone levels are similar to those usually seen in premenopausal women (James et al. 1976 ). However, unlike androstenedione, testosterone levels, before and after the menopause, show neither a diurnal rhythm nor other marked fluctuations.
In most studies it has been found that, quantitatively, the most abundant unconjugated oestrogen circulating in postmenopausal women is oestrone. The actual levels of oestrone vary somewhat, depending on the age of the population under study and the details of the assay. Oestrone is, biologically, a much less potent oestrogen than oestradiol. In our studies oestradiol concentrations are usually about 3 ngjdl-similar to those found in premenopausal women only in the menstrual and early follicular phases of the ovulatory cycle. Thus the major change in plasma steroid concentration resulting from primary ovarian failure is a decline in oestradiol levels. The plasma levels of both oestrone and oestradiol show marked asynchronous fluctuations, such that the level in a single sample may not accurately reflect the mean level. Thus calculations of blood production rates that depend on the measurement of only a few plasma oestrogen levels are probably inaccurate. Campbell et al. (1976) observed similar fluctuations in plasma oestrogen levels in women after the menopause when blood samples were obtained every 2 hours for 24 hours. In our experience, the pattern of the fluctuations does not show the diurnal rhythm observed by Vermeulen (1976) .
In women after the menopause, these fluctuations, and the variations in plasma concentrations of isotopically-labelled oestrogens observed during infusions by Hembree et al. (1969) and Pearlman et al. (1969) , may be due to alterations in hepatic blood flow (Longcope & Tait 1971) . We have also observed similar fluctuations of hormone levels in ovariectomized women, in whom episodic secretion from the ovarian stroma can of course be excluded as a possible cause of the fluctuations . The fluctuations in the levels of oestrone and oestradiol are independent of each other and also of fluctuations in the level of their androgenic prehormones, androstenedione and testosterone: thus, the mechanisms regulating peripheral conversion and interconversion of unconjugated plasma oestrogens and androgens are presently unclear.
Sources of steroids
After the menopause, the adrenal cortex is undoubtedly the major primary source of circulating androgens and oestrogens. We have studied the role of ACTH and the androgenic prehormones, testosterone and androstenedione, in the production of oestrogens by using hormone profile techniques. The subjects were postmenopausal or ovariectomized women in whom adrenal secretion had been suppressed by treatment with glucocorticoids. The results in one such woman are shown in Figure 2 . Plasma androgen and oestrogen concentrations on the control night (before treatment with dexamethasone) were similar to those previously described ( Figure I ). After treatment with dexamethasone for one week, all steroid levels were markedly lower than those on the control night. An intravenous infusion of androstenedione for 6 hours resulted in a marked increase of plasma androstenedione levels and a slight increase in testosterone and oestrone levels. Although no increase in plasma oestradiol levels was observed in the woman whose results are shown in Figure 2 , we have found considerable variations in the peripheral conversion and interconversion of steroids amongst postmenopausal women. After the infusion, plasma androstenedione and testosterone levels fell to their preinfusion values but unconjugated oestrone concentrations remained elevated. Similar patterns of androgen and oestrogen concentrations were observed when ACTH was infused instead of androstenedione . Infusion of testosterone resulted in moderate increases in plasma androstenedione and oestrone levels but not usually of oestradiol levels. After the completion of the infusion of testosterone, plasma oestrone levels remained elevated, as they did after the completion of the infusions of androstenedione and ACTH .
The results of these suppression and infusion studies suggest that, after the menopause, peripheral conversion of adrenally-secreted androstenedione is the predominant source of plasma oestrogens, particularly oestrone. These results are consistent with those obtained with (I973). However, since in our studies plasma oestrone concentrations remained elevated long after the completion of the infusions, unconjugated plasma oestrone must also be derived secondarily from other peripheral sources. Oestrone sulphate, or oestrogen stores in liver or adipose tissue, are the most probable sources. Our studies do not, however, confirm the conclusions of the isotopic studies that testosterone is androgenic prehormone for oestradiol.
Relationship of hormone levels to climacteric symptoms
Many symptoms have been attributed to ovarian failure, but, during the climacteric, superficial dyspareunia and hot flushes or sweats are the only definite consequences of ovarian failure or ovariectomy (Utian 1972) . Using the technique of hormone profiling, we have recently reported that in sexually active postmenopausal women mean plasma oestradiol concentrations were lower in those with superficial dyspareunia and flushes compared with those who had flushes as their sole climacteric symptom and those who were asymptomatic (Hutton et al. 1978) . The mean plasma oestradiol concentration in women with flushes as their sole symptom was not significantly different from the level of 3.9 ±0.4 (SEM) ng/dl observed in asymptomatic women of similar age and menopausal status. Although all the patients had clinical evidence of atrophic vaginitis, the low plasma oestradiol levels in the women with superficial dyspareunia presumably resulted in less proliferation of the vaginal epithelium than in the other women (Hammond 1976 ). This hypothesis is consistent with our recent finding ofa highly significant correlation of plasma oestradiol (but not oestrone) concentrations with the karyopyknotic index of cells obtained from the lateral vaginal wall (Morse et al. 1979) . We have found no difference in the mean plasma oestrone concentrations between the women with or without climacteric symptoms.
The cause of flushes is unknown. Mulley & Mitchell (1976) have indeed expressed doubt that oestrogens have any role at all in their cause and, hence, in their treatment. Certainly our studies of steroid and gonadotrophin profiles in women with flushes show fluctuating levels which cannot be distinguished from those in asymptomatic women (Hutton et al. 1978) .
However, investigations made during treatment of symptomatic postmenopausal women with natural oestrogen therapy indicated that when plasma oestrone levels in the first 20 hours after ingestion of the oestrogen preparation exceeded 15 ng/dl, the patient subsequently experienced relief of flushes (Hutton et al., in preparation) . We found no relationship between relief of flushes and plasma oestradiol concentration. During the subsequent course of therapy, however, the ratio of oestrone to oestradiol changes and our studies are not yet complete in this regard. Although pharmacological, rather than physiological, levels ofoestrone seem necessary to relieve flushes, oestrogens may prove to have a role in their pathogenesis. Hypothetically, an interaction of oestrogen metabolites and catecholamines in the central nervous system may be involved: this hypothesis would be consistent with the occasional onset of flushes in postmenopausal women prescribed monoamine oxidase inhibitors for depression.
Endocrine effectsof postmenopausal oestrogen therapy
Hormone replacement therapy is the term used to describe the treatment with oestrogens of women who have ovarian failure or have had an ovariectomy, with the intention of repairing their major hormone deficiency -that is, subnormal production of oestradiol. An alternative and perhaps preferable concept is the prescription of oestrogens with the intention of repairing the oestradiol deficiency in symptomatic women to the 4 ng/dl level that circulates in asymptomatic postmenopausal women.
Hormone therapy after the menopause is now usually given as 'natural' rather than as synthetic oestrogens. 'Natural' oestrogens are compounds which give rise in the circulation to oestrogens similar to those produced endogenously; in this sense, piperazine oestrone sulphate (Harmogen) and oestradiol valerate (Progynova) are pure natural oestrogen preparations. Conjugated equine oestrogens (Premarin) are not 'natural' in this sense because biologically the predominant oestrogen in the mixture is equilin (Howard & Keaty 1971) , a highly potent oestrogen that does not normally occur in humans.
The recent studies of Anderson et al. (1978) have confirmed our own observations ) that there is no difference in plasma oestrone and oestradiol concentrations during treatment with piperazine oestrone sulphate or oestradiol valerate. In both studies any increase in plasma oestradiol levels after ingestion of either oestrogen preparation was always associated with a much greater increase of plasma oestrone levels. Moreover, treatment with both compounds was associated with plasma oestrone sulphate concentrations that exceeded those found at any other time of life (Anderson et al. 1978) . The oxidation to oestrone of the orally administered oestradiol must occur in the gut because, in women after the menopause, the administration of oestradiol by other routes, such as vaginally (Rigg et al. 1978) , intramuscularly or intravenously (J D Hutton, unpublished observations) results in a preferential increase of plasma oestradiol and not plasma oestrone concentration.
Our profile studies have shown considerable variations between women in the effects of the therapy on plasma oestrogen concentrations. Thus, plasma oestradiol concentrations may rise to 10 ng/dl after one dose of cyclically administered therapy; in premenopausal women this level is usually seen only in the midfollicular phase of the ovulatory cycle. Plasma oestrone levels may rise up to 40 ng/dl, a level not usually observed in premenopausal women. Quite marked individual variations may be observed, and presumably result from differences in absorption or clearance of the oestrogens. In general, however, higher doses of the therapy usually result in higher plasma oestrogen levels.
By the third week of therapy, plasma oestrogen levels have usually reached a plateau level with little change observable in the concentrations after administration of another dose of either piperazine oestrone sulphate or oestradiol valerate. The plasma oestradiol and oestrone concentrations which are often seen at this stage of treatment (about 20 and 100 ng/dl respectively) are abnormally high, even for premenopausal women. This overdosage, which often occurs when current regimes of oestrogen preparations are prescribed, is sometimes associated with the development of abnormal endometrial hyperplasia. Monitoring oestrogen therapy by measuring plasma oestrogen levels may well be beneficial in the detection of overdosage and thus help to reduce the high incidence of abnormal proliferation of the endometrium. However, such an approach has serious limitations since it requires access to specialized laboratory facilities. Moreover, it is only applicable to oestrogen preparations that give rise to 'natural' oestrogens -and therefore cannot be used during treatment with Premarin or with synthetic oestrogens.
Conclusion
The results of our studies using hormone profiling techniques for studying steroid endocrinology after the menopause have often complemented the conclusions of studies which have either used direct sampling of the veins draining the ovaries and adrenals or isotopic techniques. For example, fluctuations in the plasma oestrogen levels occur, the adrenal cortex is the major source of postmenopausal steroids, and plasma oestrone, which is quantitatively the major unconjugated oestrogen, is derived predominantly by the extraglandular conversion of androstenedione. However, our findings are not in agreement with some of the conclusions of other workers: our studies suggest that, in the postmenopausal women, the ovary does not normally contribute significantly to either androgen or oestrogen production. Moreover, the results of infusion of unlabelled steroids indicate that the major pathway of peripheral aromatization of testosterone is to oestrone and not to oestradiol. Our studies suggest that after the menopause other, as yet undefined, sources of unconjugated plasma oestrogens exist. Superficial dyspareunia is associated with lower plasma oestradiol concentrations than those found in asymptomatic women. There are also considerable variations in the effects of pure natural oestrogen therapy on plasma oestrogen concentrations but, in general, current schedules of treatment produce levels of unconjugated oestrogens that are supraphysiological.
